NCT02432833已完成4 期
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 428
- 试验地点
- 1
- 主要终点
- Tacrolimus total daily dose (TDD) from week 3 to month 6
研究概览
简要总结
The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.
详细描述
This is a Multicentre, Open label, Randomized, Two-arm, parallel-group study to assess efficacy and safety of Envarsus® compared with tacrolimus used as per current clinical practice in the initial maintenance setting in de novo kidney transplant patients. The study will be conducted in approximately 10 european countries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's signed informed consent obtained prior to any study-related procedure;
- •Adult men and women at least 18 years of age with end-stage renal disease who are recipients (or will be recipients) of a kidney transplant from a living or deceased donor;
- •No known contraindications to the administration of tacrolimus, other macrolides and study drugs excipients;
- •Patients must agree to use a highly reliable method of birth control;
- •Donor-recipient negative cross match test, and compatible AB0 blood type;
- •Able to swallow tablets and capsules
排除标准
- •Recipient of any transplanted organ other than kidney;
- •Recipient of a previous renal transplant;
- •Recipient of a kidney from a donor after cardiac death;
- •Recipient of a kidney from an AB0 incompatible or positive cross-match donor;
- •Current (not older than 3 months) anti-HLA Panel Reactive Antibody (PRA) levels higher than 30%. Whenever PRA, either complement-dependent cytotoxicity-PRA or calculated PRA , is not available, patients who are positive on solid-phase screening assay for anti-HLA antibodies must not be enrolled;
- •Recipient of a kidney with a cold ischemia time of ≥ 30 hours;
- •White blood cells count ≤ 2.8x109 cells/L unless ANC >1.0x109/L;
- •Platelet count < 50 x109 cells/L;
- •ALT or AST levels >3 times the normal upper limit during the 30 days prior transplant procedure;
- •Current abuse of drugs or alcohol;
- •Incapable of understanding purpose and risk of study, unable to give written informed consent or unwilling to comply with study protocol;
- •Treatment with any other investigational agent in the 30 days prior to enrolment;
- •Kidney recipients and/or donors positive for HCV (HCV-RNA positive or HCV-Ab positive respectively);
- •Kidney recipients and/or donors positive for HBV (HBV-DNA or HBS-Ag positive);
- •Recipients positive for HIV;
- •Patient or donor with current diagnosis or history of malignancy within the past 5 years except basal or non-metastatic squamous cell carcinoma of the skin successfully treated;
- •Uncontrolled concomitant infection, systemic infection requiring treatment or any other unstable condition that could interfere with study objectives;
- •Severe diarrhoea, vomiting, active peptic ulcer or GI disorder that may affect absorption of tacrolimus;
- •Known hypersensitivity to tacrolimus other macrolides and study drugs excipients;
- •Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use reliable methods of contraception
研究组 & 干预措施
Prograf or Advagraf
Active Comparator
Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
干预措施: ADVAGRAF® (Drug)
Envarsus® (tacrolimus)
Experimental
prolonged-release tablets once daily and orally
干预措施: ENVARSUS® (Drug)
Prograf or Advagraf
Active Comparator
Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
干预措施: PROGRAF® (Drug)
结局指标
主要结局
Tacrolimus total daily dose (TDD) from week 3 to month 6
时间窗: from week 3 to month 6
次要结局
- Tacrolimus blood trough level (TL).(from screening to months 6)
- number of dose adjustment(from screening to months 6)
- Occurrence of treatment failure(from screening to months 6)
- Consumption of concomitant immunosuppressant medications(from screening to months 6)
- Treatment discontinuation(from screening to months 6)
- Delayed graft function(from screening to months 6)
- Acute rejection requiring treatment(from screening to months 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Envarsus XR Compared to Immediate Release TacrolimusKidney Transplant RecipientsNCT03979365Mayo Clinic261
已完成
2 期
Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical StudyKidney TransplantationNCT02970630Chiesi Farmaceutici S.p.A.28
已完成
2 期
Conversion to Envarsus Post Kidney Transplant Protects Against BK InfectionRenal Transplant InfectionNCT03762473University of Alabama at Birmingham89
撤回
3 期
A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation TreatmentRenal TransplantNCT01244659EMS
招募中
3 期
Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney TransplantationPediatric Kidney DiseaseNCT06057545University Hospital, Essen30